However, in the metastatic melanoma and breast cancer cohorts that underwent immunotherapy, patients with low FOXP1 expression demonstrated a significantly higher therapy response compared to those with high FOXP1 expression (Figures 6E, F). Here, FOXP1 is linked to metastatic melanoma.